The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1304
Tetrabenazine (Xenazine) for Huntington's Chorea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Tetrabenazine (Xenazine – Ovation Pharmaceuticals), an old drug first synthesized 50 years ago for treatment of schizophrenia,1 was recently approved by the FDA for the treatment of chorea associated with Huntington’s disease. It has been available in other countries for decades.

HUNTINGTON’S DISEASE — Huntington’s disease (HD) is an autosomal dominant, progressive neurodegenerative disorder caused by mutations in the IT-15 gene encoding the huntingtin protein. No available treatment slows the progression of the disease, but targeted treatment of depression, anxiety, cognition and chorea can improve patients’ quality of life. Standard treatments for chorea include benzodiazepines, amantadine (Symmetrel, and others) and antipsychotics such as haloperidol (Haldol, and others), risperidone (Risperdal, and others), ziprasidone (Geodon) and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tetrabenazine (Xenazine) for Huntington's Chorea
Article code: 1304c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian